References
- Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 2001;15:1232–1239.
- Weisberg E, Wright RD, McMillin DW, et al Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther 2008;7:1121–1129.
- Garrido SM, Appelbaum FR, Willman CL, Banker DE. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 2001;29:448–457.
- Bates RC, Lincz LF, Burns GF. Involvement of integrins in cell survival. Cancer Metastasis Rev 1995;14:191–203.
- Stroeken PJ, van Rijthoven EA, Boer E, Geerts D, Roos E. Cytoplasmic domain mutants of β1 integrin expressed in β1-knockout lymphoma cells, have distinct effects on adhesion, invasion and metastasis. Oncogene 2000;19:1232–1238.
- White DE, Kurpios NA, Zuo D, et al Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 2004;6:159–170.
- Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290–293.
- Butturini A, Arlinghaus RB, Gale RP. BCR/ABL and leukemia. Leuk Res 1996;20:523–529.
- Fierro FA, Taubenberger A, Puech PH, et al BCR/ABL expression of myeloid progenitors increases integrin mediated adhesion to stromal cells. J Mol Biol 2008;377:1082–1093.
- Li Y, Clough N, Sun X, et al Bcr-Abl induces abnormal cytoskeleton remodeling, beta1 integrin clustering and increased cell adhesion to fibronectin through the Abl interactor 1 pathway. J Cell Sci 2007;120:1436–1446.
- van der Kuip H, Goetz AW, Miething C, Duyster J, Aulitzky WE. Adhesion to fibronectin selectively protects Bcr-Abl cells from DNA damage-induced apoptosis. Blood 2001;98:1532–1541.
- La Rosée P, Johnson K, O'Dwyer ME, Druker BJ. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 2002;30:729–737.
- Li ZJ, Teng BX, Chen XH, et al Leukemic bone marrow stromal cells in vitro protect leukemic cell line Jurkat Cells from daunorubicin-induced apoptosis. Ai Zheng 2005;24:672–675.
- Dai T-J. Quantitative analysis of combination therapy. Chin Pharmacol Bull 1998;14:479.
- Yang Y, Lv QJ, Du QY, et al Combined effects of cantide and chemotherapeutic drugs on inhibition of tumor cells' growth in vitro and in vivo. World J Gastroenterol 2005;11:2491–2496.
- Hazlehurst LA, Dalton WS. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev 2001;20:43–50.
- Lundell BI, McCarthy JB, Kovach NL, Verfaillie C. Activation of beta1 integrins on CML progenitors reveals cooperation between beta1 integrins and CD44 in the regulation of adhesion and proliferation. Leukemia 1997;11:822–829.
- Niu ZY, Pan L, Zhang XJ, Liu YJ. Regulatory effect of integrin alpha5 and beta1 on proliferation inhibition of K562 cells induced by interferon alpha-2b. Ai Zheng 2006;25:297–302.
- Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175–1182.
- Schofield KP, Duerig J, Rushton G, Chang J. Alpha4beta1 integrin mediated adhesion of CD34 cell from patients with chronic myeloid leukemia: influence of IL-3. Br J Haematol 1999;106:524–527.
- Matsunaga T, Takemoto N, Sato T, et al Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003;9:1158–1165.
- Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93:1658–1667.
- Fukai F, Mashimo M, Akiyama K, Goto T, Tanuma S, Katayama T. Modulation of apoptotic cell death by extracellular matrix proteins and a fibronectin-derived antiadhesive peptide. Exp Cell Res 1998;242:92–99.
- Kato R, Ishikawa T, Kamiya S, et al A new type antimetastatic peptide derived from fibronectin. Clin Cancer Res 2002;8:2455–2462.
- Matsunaga T, Fukai F, Miura S, et al Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia 2008;22:353–360.